User login
Key clinical point: In this real-world study of patients with migraine, galcanezumab showed higher response rates than those reported in clinical trials, with chronic migraine (CM) and multiple failures to previous preventive medication being significant predictors of a poor response to galcanezumab.
Major finding: At 3 months of galcanezumab treatment, 55.7% of patients showed a 50% response to galcanezumab. CM (odds ratio [OR] 0.09; P = .047) and the number of previous nonresponse to preventive medication classes (OR 0.55; P = .022) were significantly associated with a poor response to galcanezumab.
Study details: This real-world study involved a prospective follow-up of 104 patients with migraine who received monthly galcanezumab.
Disclosures: This study was supported by the New Faculty Startup Fund from Seoul National University and a National Research Foundation of Korea grant. The authors declared no conflicts of interest.
Source: Kim SA et al. Predictors of galcanezumab response in a real-world study of Korean patients with migraine. Sci Rep. 2023;13:14825 (Sep 8). doi: 10.1038/s41598-023-42110-4
Key clinical point: In this real-world study of patients with migraine, galcanezumab showed higher response rates than those reported in clinical trials, with chronic migraine (CM) and multiple failures to previous preventive medication being significant predictors of a poor response to galcanezumab.
Major finding: At 3 months of galcanezumab treatment, 55.7% of patients showed a 50% response to galcanezumab. CM (odds ratio [OR] 0.09; P = .047) and the number of previous nonresponse to preventive medication classes (OR 0.55; P = .022) were significantly associated with a poor response to galcanezumab.
Study details: This real-world study involved a prospective follow-up of 104 patients with migraine who received monthly galcanezumab.
Disclosures: This study was supported by the New Faculty Startup Fund from Seoul National University and a National Research Foundation of Korea grant. The authors declared no conflicts of interest.
Source: Kim SA et al. Predictors of galcanezumab response in a real-world study of Korean patients with migraine. Sci Rep. 2023;13:14825 (Sep 8). doi: 10.1038/s41598-023-42110-4
Key clinical point: In this real-world study of patients with migraine, galcanezumab showed higher response rates than those reported in clinical trials, with chronic migraine (CM) and multiple failures to previous preventive medication being significant predictors of a poor response to galcanezumab.
Major finding: At 3 months of galcanezumab treatment, 55.7% of patients showed a 50% response to galcanezumab. CM (odds ratio [OR] 0.09; P = .047) and the number of previous nonresponse to preventive medication classes (OR 0.55; P = .022) were significantly associated with a poor response to galcanezumab.
Study details: This real-world study involved a prospective follow-up of 104 patients with migraine who received monthly galcanezumab.
Disclosures: This study was supported by the New Faculty Startup Fund from Seoul National University and a National Research Foundation of Korea grant. The authors declared no conflicts of interest.
Source: Kim SA et al. Predictors of galcanezumab response in a real-world study of Korean patients with migraine. Sci Rep. 2023;13:14825 (Sep 8). doi: 10.1038/s41598-023-42110-4